US FDA advisers to determine need for more studies of Vertex/CRISPR gene therapy

The therapy, called exagamglogene autotemcel or exa-cel, uses new gene editing CRISPR technology, and is the first-of-its-kind product to reach the FDA for an approval decision.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/zQyKsgn
via